Identification of an Immune-Related BAT Signature for Predicting Adjuvant Chemotherapy Response and Overall Survival in Patients with Resected Ductal Adenocarcinoma of the Pancreas-Reference-Cited by-同舟云学术

Identification of an Immune-Related BAT Signature for Predicting Adjuvant Chemotherapy Response and Overall Survival in Patients with Resected Ductal Adenocarcinoma of the Pancreas

Published:2022-01-21 Issue:4 Volume:26 Page:869-886
ISSN:1091-255X
Container-title:Journal of Gastrointestinal Surgery
language:en
Short-container-title:J Gastrointest Surg

Author:

Pu Ning^ORCID,Chen Qiangda,Yin Hanlin,Zhang Jicheng,Zhao Guochao,Habib Joseph R.,Chen Jie,Yu Jun,Lou Wenhui,Wu Wenchuan

Funder

National Natural Science Foundation of China

Shanghai Sailing Program

China Postdoctoral Science Foundation

National Key R&D Program

Clinical Science and Technology Innovation Project of the Shanghai ShenKang Hospital Development Centre

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s11605-021-05232-6.pdf

Reference44 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70: 7-30.

2. Yin L, Pu N, Thompson E, Miao Y, Wolfgang C, Yu J. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis. Clin Cancer Res 2021;27: 740-748.

3. Pu N, Yin L, Habib JR, et al. Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma. Future Oncol 2019;15: 3457–3465.

4. Perri G, Prakash L, Qiao W, et al. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg 2020;155: 832-839.

5. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15: 2403-2413.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor Microenvironment Responsive CD8⁺ T Cells and Myeloid‐Derived Suppressor Cells to Trigger CD73 Inhibitor AB680‐Based Synergistic Therapy for Pancreatic Cancer;Advanced Science;2023-10-22

2. Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-09

3. Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study;International Journal of Surgery;2023-07-06

4. The predictive value of prognosis and therapeutic response for STAT family in pancreatic cancer;Heliyon;2023-05

5. Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinoma;Journal for ImmunoTherapy of Cancer;2022-12